THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Results of Operations and Financial Condition

THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August8, 2017, Theravance Biopharma,Inc. issued a press release and is holding a conference call regarding its financial results for the quarter ended June30, 2017 and a business update. A copy of the press release is furnished as Exhibit99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit99.2 to this Current Report.

The information in Item 2.02 and in Item 9.01 of this Current Report on Form8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.


99.1 Press Release dated August8, 2017

99.2 Materials Accompanying the Call

Theravance Biopharma, Inc. Exhibit
EX-99.1 2 a17-19129_2ex99d1.htm EX-99.1 Exhibit 99.1     Theravance Biopharma,…
To view the full exhibit click here


Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

An ad to help with our costs